| 1 |
34718243 | Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA. | 2022 |
3 |
| 2 |
34820552 | Resetting amino acid metabolism of cancer cells by ATB0,+-targeted nanoparticles for enhanced anticancer therapy. | 2022 Mar |
1 |
| 3 |
34894465 | The first reported case of trastuzumab induced interstitial lung disease associated with anti-neutrophil cytoplasmic antibody vasculitis - A case report and a prospective cohort study on the usefulness of neutrophil derived biomarkers in monitoring vasculitis disease activity during follow-up. | 2022 Feb |
1 |
| 4 |
34896211 | IGF2BP2-dependent activation of ERBB2 signaling contributes to acquired resistance to tyrosine kinase inhibitor in differentiation therapy of radioiodine-refractory papillary thyroid cancer. | 2022 Feb 28 |
1 |
| 5 |
34958115 | Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer cells. | 2022 Feb |
1 |
| 6 |
35144424 | The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer. | 2022 Jan |
2 |
| 7 |
35158093 | Phosphoproteome of signaling by ErbB2 in ovarian cancer cells. | 2022 Apr 1 |
2 |
| 8 |
35159006 | Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer. | 2022 Jan 31 |
1 |
| 9 |
35177646 | The significance of ErbB2/3 in the conversion of induced pluripotent stem cells into cancer stem cells. | 2022 Feb 17 |
1 |
| 10 |
35248133 | INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer. | 2022 Mar 5 |
2 |
| 11 |
35270029 | Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis. | 2022 Mar 7 |
1 |
| 12 |
35276440 | Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials. | 2022 Apr |
1 |
| 13 |
35356262 | Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study. | 2022 |
2 |
| 14 |
35431974 | Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance. | 2022 |
2 |
| 15 |
35448925 | [A real world study on the relationship between drug resistance of targeted therapy and prognosis of HER-2-positive advanced breast cancer]. | 2022 Apr 23 |
1 |
| 16 |
35463361 | Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1- Mediated Gemcitabine Chemoresistance. | 2022 |
8 |
| 17 |
35503682 | Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects. | 2022 May 3 |
2 |
| 18 |
35549881 | Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini Review. | 2022 May 12 |
1 |
| 19 |
35572995 | Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection? | 2022 |
1 |
| 20 |
35617997 | Decreased HMGB1 expression contributed to cutaneous toxicity caused by lapatinib. | 2022 Jul |
2 |
| 21 |
33085768 | A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. | 2021 Mar 25 |
2 |
| 22 |
33122343 | Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. | 2021 Feb 1 |
4 |
| 23 |
33150390 | EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. | 2021 Jan 23 |
1 |
| 24 |
33429148 | CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT. | 2021 Mar |
4 |
| 25 |
33473169 | Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors. | 2021 Mar |
1 |
| 26 |
33514658 | Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells. | 2021 May |
2 |
| 27 |
33559918 | Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation. | 2021 Aug |
3 |
| 28 |
33569405 | Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study. | 2021 Jan |
2 |
| 29 |
33652033 | Qiliqiangxin alleviates Ang II-induced CMECs apoptosis by downregulating autophagy via the ErbB2-AKT-FoxO3a axis. | 2021 May 15 |
1 |
| 30 |
33742063 | Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. | 2021 Mar 19 |
1 |
| 31 |
33755862 | Personalized therapeutic strategies in HER2-driven gastric cancer. | 2021 Jul |
2 |
| 32 |
33785053 | RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. | 2021 Mar 30 |
5 |
| 33 |
33801244 | Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells. | 2021 Mar 2 |
2 |
| 34 |
33842315 | Discovery and Pharmacological Evaluation of STEAP4 as a Novel Target for HER2 Overexpressing Breast Cancer. | 2021 |
2 |
| 35 |
33862249 | Current treatment options for HER2-positive breast cancer patients with brain metastases. | 2021 May |
1 |
| 36 |
33907275 | The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. | 2021 Apr 27 |
1 |
| 37 |
33919468 | HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models. | 2021 Apr 21 |
1 |
| 38 |
33933113 | Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer. | 2021 May 1 |
1 |
| 39 |
33936677 | Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma. | 2021 Apr |
1 |
| 40 |
33939112 | Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers. | 2021 Aug |
2 |
| 41 |
33951110 | Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. | 2021 |
3 |
| 42 |
33980863 | FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. | 2021 May 12 |
1 |
| 43 |
34016991 | HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. | 2021 May 20 |
1 |
| 44 |
34034468 | [Application of neratinib in the treatment of hormone receptor and HER-2 double positive breast cancer]. | 2021 May 23 |
1 |
| 45 |
34035375 | MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro. | 2021 May 25 |
2 |
| 46 |
34045483 | Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. | 2021 May 27 |
1 |
| 47 |
34074257 | Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer. | 2021 Jun 1 |
1 |
| 48 |
34101105 | HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib. | 2021 Dec |
3 |
| 49 |
34115243 | Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. | 2021 Jul |
1 |
| 50 |
34126209 | Lapatinib enhances paclitaxel toxicity in MCF-7, T47D, and MDA-MB-321 breast cancer cells. | 2021 Sep |
2 |